Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

Published:2011 Issue:2 Volume:46 Page:103
ISSN:1738-7949
Container-title:The Korean Journal of Hematology
language:en
Short-container-title:Korean J Hematol

Author:

Jang Geundoo¹²,Yoon Dok Hyun¹,Kim Shin¹,Lee Dae Ho¹,Lee Sang-wook³,Huh Jooryung⁴,Suh Cheolwon¹

Affiliation:

1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

2. Department of Internal Medicine, Hallym University Medical Center, Seoul, Korea.

3. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

4. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/kjh.2011.46.2.103

Reference28 articles.

1. Diffuse large cell lymphoma

2. Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma

3. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the prognostic values of 18F-fluorodeoxyglucose parameters from colon and non-colon sites of involvement in diffuse large B-cell lymphoma of the colon;Scientific Reports;2020-07-29

2. Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases;Cancer Genetics;2018-12

3. Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database;Disease Markers;2018-10-16

4. Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database;DIS MARKERS;2018

5. Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era;Acta Haematologica Polonica;2015-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3